Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.
Journal
Journal of managed care & specialty pharmacy
ISSN: 2376-1032
Titre abrégé: J Manag Care Spec Pharm
Pays: United States
ID NLM: 101644425
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
entrez:
31
1
2022
pubmed:
1
2
2022
medline:
8
2
2022
Statut:
ppublish
Résumé
Health economic evaluations are comparative analyses of alternative courses of action in terms of their costs and consequences. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, published in 2013, was created to ensure health economic evaluations are identifiable, interpretable, and useful for decision making. It was intended as guidance to help authors report accurately which health interventions were being compared and in what context, how the evaluation was undertaken, what the findings were, and other details that may aid readers and reviewers in interpretation and use of the study. The new CHEERS 2022 statement replaces previous CHEERS reporting guidance. It reflects the need for guidance that can be more easily applied to all types of health economic evaluation, new methods and developments in the field, as well as the increased role of stakeholder involvement including patients and the public. It is also broadly applicable to any form of intervention intended to improve the health of individuals or the population, whether simple or complex, and without regard to context (such as health care, public health, education, social care, etc). This summary article presents the new CHEERS 2022 28-item checklist and recommendations for each item. The CHEERS 2022 statement is primarily intended for researchers reporting economic evaluations for peer reviewed journals as well as the peer reviewers and editors assessing them for publication. However, we anticipate familiarity with reporting requirements will be useful for analysts when planning studies. It may also be useful for health technology assessment bodies seeking guidance on reporting, as there is an increasing emphasis on transparency in decision making.
Identifiants
pubmed: 35098747
doi: 10.18553/jmcp.2022.28.2.146
pmc: PMC10372979
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
146-155Références
BMJ. 1996 Aug 3;313(7052):275-83
pubmed: 8704542
Health Econ. 2020 Aug;29(8):945-954
pubmed: 32412153
JAMA. 1999 Sep 15;282(11):1054-60
pubmed: 10493204
Value Health. 2017 Mar;20(3):310-319
pubmed: 28292475
Wellcome Open Res. 2020 Apr 14;5:69
pubmed: 32904933
Pharmacoeconomics. 2017 Jan;35(1):125-128
pubmed: 27928759
BMJ. 2017 Aug 2;358:j3453
pubmed: 28768629
Vaccine. 2010 Mar 8;28(11):2356-9
pubmed: 19567247
Value Health. 2014 Jan-Feb;17(1):5-14
pubmed: 24438712
Ann Intern Med. 2017 Sep 19;167(6):432-433
pubmed: 28847014
Gastroenterology. 2004 Jan;126(1 Suppl 1):S124-8
pubmed: 14978648
BMC Health Serv Res. 2008 Dec 22;8:270
pubmed: 19102752
BMJ. 2011 Apr 07;342:d1548
pubmed: 21474510
Pharmacoeconomics. 1998 Sep;14(3):259-68
pubmed: 10186465
J R Soc Med. 2016 Feb;109(2):67-77
pubmed: 26880653
Value Health. 2015 Mar;18(2):161-72
pubmed: 25773551
Value Health. 2018 Oct;21(10):1133-1149
pubmed: 30314613
Value Health. 2015 Mar;18(2):271-7
pubmed: 25773562
Int J Technol Assess Health Care. 2020 Aug 04;:1-8
pubmed: 32746954
Ann Intern Med. 1995 Jul 1;123(1):61-70
pubmed: 7762918
BMJ. 2011 Apr 11;342:d1766
pubmed: 21482590
Value Health. 2021 Jan;24(1):118-120
pubmed: 33431145
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
PLoS One. 2019 May 1;14(5):e0205633
pubmed: 31042714
Patient. 2021 Jul;14(4):429-434
pubmed: 33043427
Int J Technol Assess Health Care. 2017 Jan;33(4):424-429
pubmed: 29032786
J Clin Epidemiol. 2020 Jun;122:87-94
pubmed: 32184126
Value Health. 2016 Dec;19(8):921-928
pubmed: 27987641
Value Health. 2020 Apr;23(4):409-415
pubmed: 32327155
Value Health. 2022 Jan;25(1):10-31
pubmed: 35031088
Pharmacoeconomics. 2015 May;33(5):533-4
pubmed: 25893575
Int J Technol Assess Health Care. 2005 Spring;21(2):165-71
pubmed: 15921055
JAMA. 1996 Oct 23-30;276(16):1339-41
pubmed: 8861994
Pharmacoeconomics. 2019 Nov;37(11):1313-1320
pubmed: 31392665
PLoS Med. 2010 Feb 16;7(2):e1000217
pubmed: 20169112
Health Econ. 2016 Feb;25 Suppl 1:9-28
pubmed: 26804359
Osteoporos Int. 2011 Sep;22(9):2449-59
pubmed: 21104231
BMJ Open. 2020 Feb 13;10(2):e034463
pubmed: 32060160
Am J Obstet Gynecol. 2004 Oct;191(4):1070-6
pubmed: 15507923
Value Health. 2013 Mar-Apr;16(2):231-50
pubmed: 23538175
Health Econ Policy Law. 2009 Apr;4(Pt 2):231-45
pubmed: 19216834
Patient. 2021 Jul;14(4):379-380
pubmed: 33728553